OncoMatch/Clinical Trials/NCT06345365
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Is NCT06345365 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including mitoxantrone liposome, Ara-Cytarabine and azacitidine and Daunorubicin,Ara-Cytarabine, azacitidine for acute myeloid leukaemia.
Treatment: mitoxantrone liposome, Ara-Cytarabine and azacitidine · Daunorubicin,Ara-Cytarabine, azacitidine — Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone liposome +Ara-Cytarabine+Azacitidine), which would provide an optimal induction treatment regimen for patients with primary AML by comparing with the traditional chemotherapy regimen, DA+AZA (Daunorubicin+Ara-Cytarabine+Azacitidine).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
serum creatinine <1.5 × uln, 80 ml/min ≤ creatinine clearance ≤120 ml/min
Liver function
serum total bilirubin ≤1.5 × uln, ast/alt <2 × uln
Cardiac function
ejection fraction ef ≥50%, ultrasensitive troponin and natriuretic peptide <1.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify